Trials / Completed
CompletedNCT00905450
Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 415 (actual)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study is being conducted to identify the most effective drug concentration and dose frequency of BOL-303242-X (Mapracorat) ophthalmic suspension, for the treatment of inflammation following cataract surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BOL-303242-X | Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules. |
| DRUG | Vehicle for BOL-303242-X | Medication instilled into the study eye, subjects randomized to various drug dose schedules. |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2010-03-01
- Completion
- 2010-05-01
- First posted
- 2009-05-20
- Last updated
- 2020-09-22
- Results posted
- 2020-09-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00905450. Inclusion in this directory is not an endorsement.